| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A meta-analysis of tumour response and relapse kinetics based on 34,881 patients: A question of cancer type, treatment and line of treatment
|
Yates, James W.T.
|
|
|
150 |
C |
p. 42-52
|
artikel
|
| 2 |
Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time
|
Thomson, Sasha
|
|
|
150 |
C |
p. 203-210
|
artikel
|
| 3 |
Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study
|
Park, Joo-Hyun
|
|
|
150 |
C |
p. 73-82
|
artikel
|
| 4 |
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab
|
Dall’Olio, Filippo G.
|
|
|
150 |
C |
p. 99-107
|
artikel
|
| 5 |
Building a central repository landmarks a new era for artificial intelligence–assisted digital pathology development in Europe
|
Latonen, Leena
|
|
|
150 |
C |
p. 31-32
|
artikel
|
| 6 |
Clinical characteristics of subsequent histologically confirmed meningiomas in long-term childhood cancer survivors: A Dutch LATER study
|
Verbruggen, Lisanne C.
|
|
|
150 |
C |
p. 240-249
|
artikel
|
| 7 |
Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments
|
Zheng, Mei-Mei
|
|
|
150 |
C |
p. 23-30
|
artikel
|
| 8 |
Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma
|
Boutros, Celine
|
|
|
150 |
C |
p. 130-132
|
artikel
|
| 9 |
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases
|
Franklin, Cindy
|
|
|
150 |
C |
p. 119-129
|
artikel
|
| 10 |
D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial
|
Degiuli, M.
|
|
|
150 |
C |
p. 10-22
|
artikel
|
| 11 |
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study
|
Pinato, David J.
|
|
|
150 |
C |
p. 190-202
|
artikel
|
| 12 |
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
|
Scher, H.I.
|
|
|
150 |
C |
p. 83-94
|
artikel
|
| 13 |
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas
|
Schliemann, Christoph
|
|
|
150 |
C |
p. 143-154
|
artikel
|
| 14 |
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study
|
Duffaud, Florence
|
|
|
150 |
C |
p. 108-118
|
artikel
|
| 15 |
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells
|
Mout, Lisanne
|
|
|
150 |
C |
p. 179-189
|
artikel
|
| 16 |
Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer
|
Arai, Hiroyuki
|
|
|
150 |
C |
p. 133-142
|
artikel
|
| 17 |
Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma – A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials
|
Kurreck, Annika
|
|
|
150 |
C |
p. 250-259
|
artikel
|
| 18 |
Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance])
|
Yoon, Harry H.
|
|
|
150 |
C |
p. 214-223
|
artikel
|
| 19 |
Lenvatinib and osteonecrosis of the jaw: A pharmacovigilance study
|
Lu, Wenchao
|
|
|
150 |
C |
p. 211-213
|
artikel
|
| 20 |
Metrics of pN-staging in oral squamous cell carcinoma: An analysis of 1,905 patients
|
Mirian, Christian
|
|
|
150 |
C |
p. 33-41
|
artikel
|
| 21 |
Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment–driven analyses from the ExteNET study
|
Lüftner, Diana
|
|
|
150 |
C |
p. 268-277
|
artikel
|
| 22 |
New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of the national lockdown
|
Kempf, Emmanuelle
|
|
|
150 |
C |
p. 260-267
|
artikel
|
| 23 |
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study
|
Fujimoto, Daichi
|
|
|
150 |
C |
p. 63-72
|
artikel
|
| 24 |
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium
|
Pasqualini, Claudia
|
|
|
150 |
C |
p. 53-62
|
artikel
|
| 25 |
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
|
Buti, Sebastiano
|
|
|
150 |
C |
p. 224-231
|
artikel
|
| 26 |
Re: ERCC3, a new ovarian cancer susceptibility gene?
|
Soukupova, Jana
|
|
|
150 |
C |
p. 278-280
|
artikel
|
| 27 |
Response to letter entitled: Re: ERCC3 a new ovarian cancer susceptibility gene?
|
Stradella, Agostina
|
|
|
150 |
C |
p. 281-282
|
artikel
|
| 28 |
Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER)
|
Tougeron, David
|
|
|
150 |
C |
p. 232-239
|
artikel
|
| 29 |
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients
|
Mansi, Laura
|
|
|
150 |
C |
p. 1-9
|
artikel
|
| 30 |
The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials
|
Fujiwara, Yu
|
|
|
150 |
C |
p. 168-178
|
artikel
|
| 31 |
The European Union and personalised cancer medicine
|
Hickman, John A.
|
|
|
150 |
C |
p. 95-98
|
artikel
|
| 32 |
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
|
Corti, Francesca
|
|
|
150 |
C |
p. 155-167
|
artikel
|
Tijdschrift beschrijving